The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers.

CONTEXT The pathobiology of the metabolic syndrome remains unclear. The central nervous system is likely to be involved via regulation of eating, physical activity, blood pressure, and metabolism. OBJECTIVE The objective of this study was to test the hypothesis that low central serotonergic activity is associated with the metabolic syndrome. DESIGN, SETTING, PARTICIPANTS This was a cross-sectional study of 345 healthy community volunteers, aged 30-55 yr, not taking medications for hypertension, lipid disorders, or diabetes. OUTCOME MEASURES Central serotonergic responsivity was assessed with the iv citalopram challenge test. The serum prolactin area under the curve (AUC) over 150 min was calculated, and all analyses were adjusted for age, sex, plasma citalopram concentration, and baseline prolactin. The metabolic syndrome was defined according to the National Cholesterol Education Program (NCEP) and International Diabetes Federation (IDF) criteria. Insulin resistance was estimated by homeostasis model assessment. RESULTS Compared with other individuals, persons meeting either NCEP or IDF criteria for the metabolic syndrome had lower mean prolactin responses (P < 0.05 for both). Using logistic regression, a decrease in prolactin AUC of 1 sd (-13.6 ng/ml.h) more than doubled the odds of having the metabolic syndrome (NCEP criteria: odds ratio, 2.38; 95% confidence interval, 1.14-4.97; P = 0.02; IDF criteria: odds ratio, 2.80; 95% confidence interval, 1.48-5.30; P = 0.002). Finally, the prolactin AUC was negatively associated with insulin resistance (beta = -0.03, P = 0.02). CONCLUSIONS Corroborating previous evidence, the metabolic syndrome was associated with diminished brain serotonergic activity as reflected in a comparative blunting of the prolactin response to a selective serotonergic challenge. This association may have implications for the etiology, prevention, and treatment of the metabolic syndrome.

[1]  Gwenn S. Smith,et al.  Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences , 2005, Psychopharmacology.

[2]  J. Flory,et al.  A comparison of d,l-fenfluramine and citalopram challenges in healthy adults , 2004, Psychopharmacology.

[3]  A. Kalsbeek,et al.  Central nervous determination of food storage--a daily switch from conservation to expenditure: implications for the metabolic syndrome. , 2003, European journal of pharmacology.

[4]  A. Kalsbeek,et al.  Autonomic nervous control of white adipose tissue : studies on the role of the brain in body fat distribution , 2005 .

[5]  S. Manuck,et al.  White-coat hypertension and carotid artery atherosclerosis: a matching study. , 2000, Archives of internal medicine.

[6]  J. Horáček,et al.  The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers , 1999, Psychoneuroendocrinology.

[7]  C. S. Paulose,et al.  Alpha2 adrenergic and high affinity serotonergic receptor changes in the brain stem of streptozotocin-induced diabetic rats. , 1999, Life sciences.

[8]  L. Tecott,et al.  Knockout Corner: Neurobehavioural consequences of a serotonin 5-HT(2C) receptor gene mutation. , 1999, The international journal of neuropsychopharmacology.

[9]  A. Astrup,et al.  Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. , 1995, Metabolism: clinical and experimental.

[10]  A. Fatatis,et al.  Pharmacological characterization of serotonin receptors involved in the control of prolactin secretion. , 1989, European journal of pharmacology.

[11]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[12]  G. Tedeschi,et al.  Prolactin secretion in man: a useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine. , 1983, British journal of clinical pharmacology.

[13]  D. Allison,et al.  Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. , 2005, Archives of general psychiatry.

[14]  J. Flory,et al.  Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  P. Goodnick.  Use of antidepressants in treatment of comorbid diabetes mellitus and depression as well as in diabetic neuropathy. , 2001, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[16]  L. Yatham,et al.  Neuroendocrine probes of serotonergic function: a critical review. , 1993, Life sciences.

[17]  B. Guy-grand.  Clinical studies with d-fenfluramine. , 1992, The American journal of clinical nutrition.